Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | NTB-928 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on NTB-928, a putative T-cell engager targeting FOLR1 and CD3 (Jul 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| NTB-928 | NTB928NTB 928 | FOLR1-targeted Therapy 26 | Limited information is currently available on NTB-928, a putative T-cell engager targeting FOLR1 and CD3 (Jul 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07690189 | Phase I | NTB-928 | Study of NTB-928 in R/R OC | Recruiting | USA | 0 |